32 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in May 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
May 2028
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2040 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends Apr 2037 · High confidence
Coronavirus Vaccine Formulations
US 11,541,112
The most cited patent in this portfolio, cited by 44 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Modified RSV F Proteins and Methods of Their Use
US 10,022,437
Cited by 31 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Vaccine Compositions Having Improved Stability and Immunogenicity
US 11,253,585
Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 1, 2027The maintenance fee for Vaccine Compositions Having Improved Stability and Immunogenicity (US 10,426,829) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for Influenza Vaccine (US 10,485,863) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 2 fees due Aug 13, 2027
- 1 fee due Sep 26, 2027The maintenance fee for Methods and Compositions for Inducing Immune Responses Against Clostridium Difficile (US 11,938,179) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 3 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified RSV F Proteins and Methods of Their Use | 8 in force | to Oct 2031 |
| Coronavirus Vaccine Formulations | 7 in force | to Apr 2043 |
| Vaccine Compositions Having Improved Stability and Immunogenicity | 4 in force | to Apr 2037 |
| Multivalent Influenza Nanoparticle Vaccines | 2 in force | to May 2039 |
| Methods and Compositions for Inducing Immune Responses Against Clostridium Difficile | 2 in force | to Mar 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,381,239 | Novel VLPS Derived from Cells That Do Not Express a Viral Matrix or Core Protein In force · High confidence | In force | High confidence | |
| US 8,697,088 | Novel VLPS Derived from Cells That Do Not Express a Viral Matrix or Core Protein In force · High confidence | In force | High confidence | |
| US 9,675,685 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 9,717,786 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 9,731,000 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 10,022,437 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 11,052,146 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 11,446,374 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 12,357,684 | Modified RSV F Proteins and Methods of Their Use In force · High confidence | In force | High confidence | |
| US 10,736,958 | Influenza Vaccine held by Novavax AB In force · High confidence | In force | High confidence |
Also on record, not counted in the 32: 1 patent in force now held by others · 31 patents ended · 28 applications pending · 38 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.